Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How pH and sulfation shape human heparanase structure, stability, and substrate recognition.

Archives of biochemistry and biophysics·2026
Same author

Shining a light on substrate affinity of glutamate-binding protein. Single-molecule insights into pH-modulated glutamate binding.

Scientific reports·2026
Same author

The Volatile Signature: Tracking Ripening Dynamics to Ensure Goat Cheese Quality.

Sensors (Basel, Switzerland)·2026
Same author

Fluorescence Correlation Spectroscopy (FCS) Unlocks the Presence of Microcystin-LR in Water.

Life (Basel, Switzerland)·2026
Same author

VOCs Profiling and Quality Assessment of Milk Employing Odorant-Binding Proteins-Based Fluorescence Biosensor.

International journal of molecular sciences·2026
Same author

Biology of novel LpxC inhibitors for <i>Neisseria gonorrhoeae</i> informs strategy for therapeutic innovation.

Microbiology spectrum·2026

Related Experiment Video

Updated: Jun 15, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Human galectin-3 interacts with two anticancer drugs.

Vanya P Bogoeva1, Antonio Varriale, Constance M John

  • 1Institute of Molecular Biology, Bulgarian Academy of Sciences, Sofia, Bulgaria. vanya.bogoeva@gmail.com

Proteomics
|March 9, 2010
PubMed
Summary
This summary is machine-generated.

Human galectin-3 (hGal-3) binds two anticancer agents, bohemine and Zn porphyrin (ZnTPPS(4)), with high affinity. This interaction, distinct from carbohydrate binding, suggests potential for targeted cancer drug delivery using hGal-3.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Related Experiment Videos

Last Updated: Jun 15, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Area of Science:

  • Biochemistry and Molecular Biology
  • Cancer Research
  • Drug Discovery

Background:

  • Human galectin-3 (hGal-3) is a protein involved in cell regulation and cancer.
  • Extracellular hGal-3 can crosslink cells via interactions with cell surface glycoproteins and cancer antigens.

Purpose of the Study:

  • To investigate the binding interaction of hGal-3 with two anticancer agents: bohemine and zinc protoporphyrin (ZnTPPS(4)).
  • To determine if these agents bind to the carbohydrate recognition site of hGal-3.

Main Methods:

  • Fluorescence spectroscopy was employed to study the binding kinetics.
  • Circular dichroism (CD) spectroscopy was used to analyze structural changes in hGal-3 upon compound binding.

Main Results:

  • Bohemine exhibited a dissociation constant (K-D) of 0.23±0.05 μM, indicating a single binding site.
  • ZnTPPS(4) demonstrated high-affinity binding (K-D = 0.18–0.20 μM) independent of lactose, suggesting a distinct binding site.
  • CD spectra revealed that both compounds induced changes in the secondary structure of hGal-3.

Conclusions:

  • Bohemine and ZnTPPS(4) bind hGal-3 with high affinity at a site separate from the carbohydrate-binding site.
  • Given hGal-3's role in binding cancer antigens, these findings support its potential as a platform for targeted cancer drug delivery.